dc.contributor.author | Crespo, M | en_US |
dc.contributor.author | Navarro, J | en_US |
dc.contributor.author | Moreno, S | en_US |
dc.contributor.author | Sanz, J | en_US |
dc.contributor.author | Márquez, M | en_US |
dc.contributor.author | Zamora, J | en_US |
dc.contributor.author | Ocampo, A | en_US |
dc.contributor.author | Iribaren, JA | en_US |
dc.contributor.author | Rivero, A | en_US |
dc.contributor.author | Llibre, JM | en_US |
dc.date.accessioned | 2016-08-09T10:42:16Z | |
dc.date.available | 2016-02-28 | en_US |
dc.date.issued | 2017-10 | en_US |
dc.date.submitted | 2016-08-06T23:38:34.714Z | |
dc.identifier.other | 10.1016/j.eimc.2016.02.029 | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/13952 | |
dc.description.abstract | INTRODUCTION: Limited data is available regarding the hepatic safety of maraviroc in patients co-infected with HIV and HCV and/or HBV. Our objective was to compare the hepatic safety profile and fibrosis progression in HIV-mono-infected patients and co-infected with HCV and/or HBV treated with maraviroc. METHODS: Retrospective multicentre cohort study of HIV-infected patients receiving treatment with a maraviroc-containing regimen in 27 hospitals in Spain. RESULTS: A total of 667 patients were analyzed, of whom 313 were co-infected with HCV (n=282), HBV (n=14), or both (n=17). Maraviroc main indications were salvage therapy (52%) and drug toxicity (20%). Grade 3-4 hypertransaminasaemia (AST/ALT >5 times ULN) per 100 patient-years of maraviroc exposure, was 5.84 (95% CI, 4.04-8.16) and 1.23 (95% CI, 0.56-2.33) in co-infected and HIV-mono-infected patients, respectively (incidence rate ratio, 4.77; 95% CI, 2.35-10.5). However, the degree of aminotransferase abnormalities remained stable throughout the study in both groups, and no significant between-group differences were seen in the cumulative proportion of patients showing an increase in AST/ALT levels greater than 3.5 times baseline levels. No between-group differences were seen in liver fibrosis over time. With a maraviroc median exposure of 20 months (IQR, 12-41), two patients (0.3%) discontinued maraviroc because of grade 4 hepatitis, and other 2 died due to complications associated to end-stage-liver disease. CONCLUSIONS: Maraviroc-containing regimens showed a low incidence of hepatitis in a large Spanish cohort of HIV-infected patients, including more than 300 patients co-infected with HCV and/or HBV. Co-infection did not influence the maximum liver enzyme level or the fibrosis progression throughout the study. | en_US |
dc.format.extent | 493 - 498 | en_US |
dc.language | eng spa | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Enferm Infecc Microbiol Clin | en_US |
dc.subject | Co-infection | en_US |
dc.subject | Coinfección | en_US |
dc.subject | Fibrosis hepática | en_US |
dc.subject | HBV | en_US |
dc.subject | HCV | en_US |
dc.subject | HIV | en_US |
dc.subject | Hepatitis | en_US |
dc.subject | Liver fibrosis | en_US |
dc.subject | Maraviroc | en_US |
dc.subject | VHB | en_US |
dc.subject | VHC | en_US |
dc.subject | VIH | en_US |
dc.subject | Adult | en_US |
dc.subject | Anti-HIV Agents | en_US |
dc.subject | Chemical and Drug Induced Liver Injury | en_US |
dc.subject | Coinfection | en_US |
dc.subject | Disease Progression | en_US |
dc.subject | Female | en_US |
dc.subject | Follow-Up Studies | en_US |
dc.subject | HIV Infections | en_US |
dc.subject | HIV-1 | en_US |
dc.subject | Hepatitis B | en_US |
dc.subject | Hepatitis C | en_US |
dc.subject | Humans | en_US |
dc.subject | Liver Cirrhosis | en_US |
dc.subject | Male | en_US |
dc.subject | Maraviroc | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Proportional Hazards Models | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Spain | en_US |
dc.title | Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. | en_US |
dc.type | Article | |
dc.rights.holder | © 2016 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved | |
dc.identifier.doi | 10.1016/j.eimc.2016.02.029 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/27061975 | en_US |
pubs.issue | 8 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 35 | en_US |
dcterms.dateAccepted | 2016-02-28 | en_US |